Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NDI Guidance Could Heighten Need To Protect DSHEA’s Intent – Harkin

This article was originally published in The Tan Sheet

Executive Summary

Sen. Tom Harkin calls on dietary supplement industry firms to “be vigilant" in protecting their rights under the Dietary Supplement Health and Education Act once FDA publishes the new dietary ingredient notification guidance.

You may also be interested in...

Low NDI Notice Compliance Sets Stage For Enforcement – FDA’s Fabricant

The volume of noncompliant supplement ingredients on the market likely will prompt an uptick in enforcement after FDA releases its NDI notification guidance, which will draw attention to the problem, dietary supplement program chief Daniel Fabricant says.

In Brief

Novartis appeals Excedrin case to NARB

Dietary Supplement Caucus Goes Bicameral, Adds Hatch, Harkin As Co-Chairs

Sens. Orrin Hatch and Tom Harkin are no strangers to dietary supplement firms as longtime champions for their interests, but for the first time they are members of the industry's congressional caucus.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts